OBJECTIVES:  In a study aimed at measuring the effectiveness of Adalimumab in HRQL of moderate to severe RA patients as prescribed by rheumatologists in normal clinical setting in Greece we examined the HRQL levels and the correlation among HRQL measures in RA patients. METHODS:  An open label, 52-week follow-up study of 120 patients is being conducted in ten hospitals. In total, 36 RA patients are so far enrolled and 21 CRFs have been collected. Two generic instruments -the EQ-5D Questionnaire and the Medical Outcome Study (MOS) Short-Form 36 (SF-36)- and one disease-specific–the Health Assessment Questionnaire (HAQ)- were implemented. Correlation analysis was used to identify the relationship among HRQL measures, and reliability analysis to test internal consistency. RESULTS:  RA patients' mean age was 58.5 years (Std.D. 10.8), while 81% were women. The mean values of the SF-36 scales were: VT 35.2 (Std.D. 33.3), SF 48.2 (Std.D. 38.8), RE 34.9 (Std.D. 47.6), MH 48.7 (Std.D. 21.6), PF 34.5 (Std.D. 22.6), RP 11.9 (Std.D. 28), BP 33.5 (Std.D. 18.6), GH 38.5 (Std.D. 19.7). 81% of RA patients had moderate mobility problems and 61.9% with self-care. Moderate problems in doing usual activities had 81%, while 42.9% complained about pain/discomfort. 14.3% of RA patients were extremely anxious/depressed. The mean VAS value was 28.6 (Std.D. 27.5), while mean HAQ score 1.2 (Std.D. 1.3). A statistically significant correlation was found between HAQ and all the SF-36 scales. Correlation coefficients ranged from -0.471 (GH) to -0.786 (PF) at level 0.01. HAQ was strongly correlated with the mobility (r=0.531), self-care (r=0,546), and usual activity (r=0,513) of the EQ-5D at level 0.05. Cronbach’ alpha coefficients for HAQ, SF-36 and EQ-5D were 0.856, 0.879 and 0.552 respectively. CONCLUSIONS: RA patients recorded significantly low levels of HRQL. The study reveals a statistically significant correlation among HAQ, SF-36 and EQ-5D.